For years, the biggest drug story in America excluded the people who might benefit most. Federal law bars Medicare from paying for weight-loss medicine, so seniors watched the GLP-1 era from the bench.
That changed this week. Medicare has begun covering GLP-1 weight-loss drugs — Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound — through a new program called Bridge.
The price to the patient: a $50 monthly copay — the flat share you pay while the program covers the rest.
Two facts can be true at once here. This is a real milestone, and it comes with an expiration question.
Who gets in
The eligibility rules are tighter than the drugs’ FDA labels. You need a higher weight threshold or a serious related condition.
Already getting a GLP-1 through standard Medicare drug benefits? You are excluded from Bridge.
Of the 13 million-plus Medicare enrollees who are overweight or obese, the health-research group KFF estimates about 3.8 million qualify. Medicare’s own director expects the launch to reach the ‘single-digit millions.’
Expect paperwork friction early. Doctors must attest to strict criteria, and pharmacies are still learning the new claim channels.
In plain terms: the door is real, but it is narrower than the headlines suggest.
Read ‘bridge’ literally
Now the part that belongs in your planning file, not just your news feed: the program is designed to be temporary.
Bridge was meant as a six-month on-ramp to a permanent, insurer-run benefit called Balance. That handoff already fell apart once — too few private plans would take on the cost.
So the government shelved Balance indefinitely and is footing the bill through 2027. Insurers could step in for 2028. Nothing compels them to.
Remember who blinked last time. The insurers did — and nothing says they have changed their minds.
The private market is moving the other direction, too. More than a quarter of big employers are adding coverage rules this year or next, and many plan to drop weight-loss coverage entirely.
The honest summary: a real benefit today, an open question after 2027.
Programs with sunset dates deserve sunset planning. We treat the copay as today’s price, not a promise.
Three moves
One: if you or a spouse might qualify, ask your doctor about Bridge eligibility now, before the paperwork line gets long.
Two: if a GLP-1 becomes part of your life, budget it as a line item that could snap back to full price — roughly a four-figure swing per person, per year. The $50 copay is a gift, not a guarantee.
Three: if you plan to retire before 65, this is one more reason the health-cost bridge years need real numbers in the plan, not hopes.
The pattern behind all three moves is the same. Use the benefit; never lean the whole budget on it.
One more note for investors. We own the pharma franchises rather than trade their headlines. Analysts peg Bridge at roughly $3 billion a year for the drugmakers, against $80 billion of GLP-1 sales already flowing. That is a variable to watch — not yet one to bank.